Kymera Therapeutics (NASDAQ:KYMR) Director Sells 246,330 Shares

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Bruce Booth sold 246,330 shares of the company’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $98.52, for a total value of $24,268,431.60. Following the completion of the sale, the director directly owned 617,663 shares of the company’s stock, valued at approximately $60,852,158.76. This represents a 28.51% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bruce Booth also recently made the following trade(s):

• On Thursday, June 18th, Bruce Booth sold 115,056 shares of Kymera Therapeutics stock. The shares were sold at an average price of $91.01, for a total transaction of $10,471,246.56.
• On Wednesday, June 17th, Bruce Booth sold 105,071 shares of Kymera Therapeutics stock. The stock was sold at an average price of $90.38, for a total transaction of $9,496,316.98.
• On Wednesday, June 17th, Bruce Booth sold 11,741 shares of Kymera Therapeutics stock. The stock was sold at an average price of $89.98, for a total transaction of $1,056,455.18.
• On Monday, June 22nd, Bruce Booth sold 31,798 shares of Kymera Therapeutics stock. The shares were sold at an average price of $103.75, for a total transaction of $3,299,042.50.
• On Wednesday, April 22nd, Bruce Booth sold 100 shares of Kymera Therapeutics stock. The shares were sold at an average price of $90.08, for a total transaction of $9,008.00.
• On Wednesday, April 22nd, Bruce Booth sold 5,900 shares of Kymera Therapeutics stock. The shares were sold at an average price of $89.96, for a total transaction of $530,764.00.
• On Wednesday, April 15th, Bruce Booth sold 3,135 shares of Kymera Therapeutics stock. The stock was sold at an average price of $90.10, for a total transaction of $282,463.50.
• On Wednesday, April 15th, Bruce Booth sold 2,200 shares of Kymera Therapeutics stock. The stock was sold at an average price of $89.95, for a total transaction of $197,890.00.
• On Tuesday, April 14th, Bruce Booth sold 4,159 shares of Kymera Therapeutics stock. The shares were sold at an average price of $89.97, for a total transaction of $374,185.23.

Kymera Therapeutics Trading Up 10.0%

Shares of NASDAQ:KYMR traded up $9.02 on Monday, reaching $99.45. 2,891,041 shares of the company traded hands, compared to its average volume of 589,977. The business’s 50-day simple moving average is $83.41 and its 200 day simple moving average is $81.31. Kymera Therapeutics, Inc. has a 52 week low of $36.65 and a 52 week high of $105.00. The stock has a market capitalization of $8.18 billion, a P/E ratio of -27.86 and a beta of 2.02.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Thursday, April 30th. The company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.18. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The firm had revenue of $34.37 million for the quarter, compared to the consensus estimate of $8.27 million. During the same quarter in the previous year, the business earned ($0.82) earnings per share. The company’s quarterly revenue was up 55.5% on a year-over-year basis. Sell-side analysts expect that Kymera Therapeutics, Inc. will post -3.25 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. SG Americas Securities LLC lifted its holdings in Kymera Therapeutics by 169.1% in the 4th quarter. SG Americas Securities LLC now owns 22,693 shares of the company’s stock worth $1,766,000 after buying an additional 14,261 shares during the period. Hudson Bay Capital Management LP increased its stake in shares of Kymera Therapeutics by 362.7% during the third quarter. Hudson Bay Capital Management LP now owns 23,134 shares of the company’s stock valued at $1,309,000 after buying an additional 18,134 shares during the period. Eagle Health Investments LP bought a new position in shares of Kymera Therapeutics during the fourth quarter valued at approximately $10,606,000. Vanguard Group Inc. raised its holdings in shares of Kymera Therapeutics by 15.6% during the fourth quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock valued at $487,685,000 after acquiring an additional 845,922 shares in the last quarter. Finally, Holocene Advisors LP bought a new position in shares of Kymera Therapeutics during the third quarter valued at approximately $47,563,000.

Wall Street Analyst Weigh In

A number of equities analysts have commented on KYMR shares. Wall Street Zen raised Kymera Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 2nd. Loop Capital set a $97.00 price objective on Kymera Therapeutics in a research note on Monday, June 8th. Royal Bank Of Canada restated an “outperform” rating and issued a $108.00 target price on shares of Kymera Therapeutics in a report on Thursday, February 26th. Jefferies Financial Group began coverage on shares of Kymera Therapeutics in a research note on Monday, March 16th. They issued a “buy” rating and a $110.00 target price on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Kymera Therapeutics in a report on Tuesday, April 21st. One research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $117.14.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.